Stifel Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $31
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Ben Burnett has initiated coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and a price target of $31.
October 19, 2023 | 8:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel has initiated coverage on Cabaletta Bio with a Buy rating and a price target of $31, which could potentially drive the stock price up.
The initiation of coverage by Stifel with a Buy rating indicates a positive outlook for Cabaletta Bio. The price target of $31, if higher than the current price, suggests that the analyst sees significant upside potential, which could attract investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100